Evidence map›Paper›PMID 28631130›Full record

ArticleJournal of computer-aided molecular design2017

New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

D Fernández, R Ramis, J Ortega-Castro, R Casasnovas, B Vilanova, J Frau

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

D FernándezDepartment de Química, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, 07122, Palma, Spain.
R RamisDepartment de Química, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, 07122, Palma, Spain.
J Ortega-CastroDepartment de Química, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, 07122, Palma, Spain. joaquin.castro@uib.es.
R CasasnovasInstitute of Neuroscience and Medicine INM-9, Institute for Advanced Simulations IAS-5, Computational Biomedicine, Forschungszentrum Jülich, Jülich, Germany.
B VilanovaDepartment de Química, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, 07122, Palma, Spain.
J FrauDepartment de Química, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, 07122, Palma, Spain.
Health Research Institute of the Balearic Islands · ESServei de Salut de les Illes Balears · ESForschungszentrum Jülich · DEUniversitat de les Illes Balears · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pamidronate, alendronate, APHBP and neridronate are a group of drugs, known as second-generation bisphosphonates (2G-BPs), commonly used in the treatment of bone-resorption disorders, and recently their use has been related to some collateral side effects. The therapeutic activity of 2G-BPs is related to the inhibition of the human Farnesyl Pyrophosphate Synthase (hFPPS). Available inhibitory activity values show that 2G-BPs act time-dependently, showing big differences in their initial inhibitory activities but similar final IC

Indexed as

Molecular Dynamics SimulationAlendronateBinding SitesBone Density Conservation AgentsDiphosphonatesDrug DiscoveryGeranyltranstransferaseHemiterpenesHumansOrganophosphorus CompoundsPamidronateProtein BindingStructure-Activity RelationshipThermodynamics6-amino-1-hydroxyhexane-1,1-diphosphonateAlendronateBone Density Conservation AgentsDiphosphonatesGeranyltranstransferaseHemiterpenesisopentenyl pyrophosphateOrganophosphorus CompoundsPamidronateBinding free energyHuman farnesyl pyrophosphate synthaseInhibitorsMolecular dynamicsSecond-generation bisphosphonates

Identifiers

PMID28631130
OpenAlexW2655255793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.